Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) is set to post its quarterly earnings results after the market closes on Tuesday, November 14th. Analysts expect Taysha Gene Therapies to post earnings of ($0.13) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.07). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, analysts expect Taysha Gene Therapies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $1.51 on Friday. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The company has a market capitalization of $281.37 million, a price-to-earnings ratio of -0.66 and a beta of 0.13. The firm’s fifty day moving average price is $2.70 and its 200 day moving average price is $1.59.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TSHA shares. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, August 15th. Cantor Fitzgerald lifted their price target on shares of Taysha Gene Therapies from $2.00 to $7.00 and gave the stock an “overweight” rating in a research note on Monday, August 14th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, September 20th. Truist Financial dropped their price target on shares of Taysha Gene Therapies from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 20th. Finally, Robert W. Baird boosted their target price on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 15th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.89.

Insider Activity at Taysha Gene Therapies

In other news, CFO Kamran Alam sold 33,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $2.33, for a total transaction of $76,890.00. Following the completion of the transaction, the chief financial officer now directly owns 258,042 shares of the company’s stock, valued at $601,237.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Paul B. Manning purchased 16,466,667 shares of the stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average price of $0.90 per share, for a total transaction of $14,820,000.30. Following the completion of the transaction, the insider now owns 16,466,667 shares of the company’s stock, valued at $14,820,000.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kamran Alam sold 33,000 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was sold at an average price of $2.33, for a total transaction of $76,890.00. Following the completion of the transaction, the chief financial officer now owns 258,042 shares of the company’s stock, valued at approximately $601,237.86. The disclosure for this sale can be found here. Insiders acquired a total of 17,300,000 shares of company stock valued at $15,570,000 in the last quarter. Insiders own 2.25% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Maven Securities LTD bought a new position in Taysha Gene Therapies in the 4th quarter worth approximately $34,000. AQR Capital Management LLC bought a new position in shares of Taysha Gene Therapies in the second quarter worth $38,000. XTX Topco Ltd bought a new position in shares of Taysha Gene Therapies in the first quarter worth $68,000. Bank of America Corp DE grew its position in Taysha Gene Therapies by 172.0% in the 1st quarter. Bank of America Corp DE now owns 137,001 shares of the company’s stock valued at $109,000 after buying an additional 86,625 shares in the last quarter. Finally, Occudo Quantitative Strategies LP grew its position in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company’s stock valued at $115,000 after buying an additional 4,702 shares in the last quarter. Institutional investors own 25.91% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.